Lipid-lowering for peripheral arterial disease of the lower limb.

BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease. It may also reduce cardiovascular events and/or local disease progression in people with lower limb peripheral arterial disease (PAD). OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality, cardiovascular events and local disease progression in patients with PAD of the lower limb. SEARCH STRATEGY The authors searched The Cochrane Peripheral Vascular Diseases Group's Specialised Register (last searched February 2007) and the Cochrane Central Register of Controlled Trials (CENTRAL) (last searched Issue 2, 2007) for publications describing randomised controlled trials of lipid-lowering therapy in peripheral arterial disease of the lower limb. SELECTION CRITERIA Randomised controlled trials of lipid-lowering therapy in patients with PAD of the lower limb. DATA COLLECTION AND ANALYSIS Three authors independently assessed trial quality and extracted data. MAIN RESULTS Eighteen trials were included, involving a total of 10,049 participants. Trials differed considerably in their inclusion criteria, outcomes measured, and type of lipid-lowering therapy used. Only one trial (PQRST) reported a detrimental effect of active treatment on blood lipid/lipoprotein levels. The pooled results from all eligible trials indicated that lipid-lowering therapy had no statistically significant effect on overall mortality (Odds Ratio (OR) 0.86; 95% Confidence Interval (CI) 0.49 to 1.50) or on total cardiovascular events (OR 0.8; 95% CI 0.59 to 1.09). However, subgroup analysis which excluded PQRST showed that lipid-lowering therapy significantly reduced the risk of total cardiovascular events (OR 0.74; CI 0.55 to 0.98). This was primarily due to a positive effect on total coronary events (OR 0.76; 95% CI 0.67 to 0.87). Greatest evidence of effectiveness came from the use of simvastatin in people with a blood cholesterol >/= 3.5 mmol/litre (HPS). Pooling of the results from several small trials on a range of different lipid-lowering agents indicated an improvement in total walking distance (Weighted Mean Difference (WMD) 152 m; 95% CI 32.11 to 271.88) and pain-free walking distance (WMD 89.76 m; 95% CI 30.05 to 149.47) but no significant impact on ankle brachial index (WMD 0.04; 95% CI -0.01 to 0.09). AUTHORS' CONCLUSIONS Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD. It may also improve local symptoms. Until further evidence on the relative effectiveness of different lipid-lowering agents is available, use of a statin in people with PAD and a blood cholesterol level >/=3.5 mmol/litre is most indicated.

[1]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[2]  S. Nilsson,et al.  The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. , 1996, Atherosclerosis.

[3]  W. Aronow,et al.  Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. , 2003, The American journal of cardiology.

[4]  B. Lewis.  Randomised controlled trial of the treatment of hyperlipidaemia on progression of atherosclerosis. , 2009, Acta medica Scandinavica. Supplementum.

[5]  M. Mclaren,et al.  Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment , 1999, Vascular medicine.

[6]  E. Nye,et al.  The treatment of intermittent claudication with betapyridyl carbinol over two years. , 1973, Atherosclerosis.

[7]  G. Lip,et al.  Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. , 2001, The American journal of cardiology.

[8]  P. Foà,et al.  A Clinical Evaluation of Diethanolamine Salt of p-Tolyl- Methylcarbinol Camphoric Acid (Gallogen) in Arteriosclerosis Obliterans , 1963, Angiology.

[9]  J. Illnait,et al.  Effects of Policosanol and Lovastatin in Patients with Intermittent Claudication: A Double-Blind Comparative Pilot Study , 2003, Angiology.

[10]  S. Nilsson,et al.  Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[11]  W. Applegate,et al.  Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). , 2000, American heart journal.

[12]  R. Collins,et al.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[13]  D. Hunninghake,et al.  Niacin treatment increases plasma homocyst(e)ine levels. , 1999, American heart journal.

[14]  F. Casalini,et al.  [Evaluation of a sulfomucopolysaccharide (3GS) in the treatment of hyperlipoproteinemias]. , 1982, La Clinica terapeutica.

[15]  B. Lewis,et al.  A controlled trial of plasma lipid reduction in peripheral atherosclerosis—an interim report , 1982, The British journal of surgery.

[16]  R F Heller,et al.  Reducing blood cholesterol levels in patients with peripheral vascular disease: dietitian or diet fact sheet? , 1989, The Medical journal of Australia.

[17]  S. Nilsson,et al.  Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report. , 1988, The American journal of cardiology.

[18]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[19]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[20]  A. Castelluccio,et al.  Effect of sulodexide on blood viscosity in patients with peripheral vascular disease. , 1991, Current medical research and opinion.

[21]  S. Nilsson,et al.  Probucol Quantitative Regression Swedish Trial: new angiographic technique to measure atheroma volume of the femoral artery. , 1988, The American journal of cardiology.

[22]  M. Hromadka,et al.  [Statins in the treatment of patients with arterial occlusive disease of the lower extremities]. , 2001, Vnitrni lekarstvi.

[23]  R. L. Johnson,et al.  The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. , 1987, Controlled clinical trials.

[24]  J. Dormandy,et al.  The natural history of claudication: risk to life and limb. , 1999, Seminars in vascular surgery.

[25]  J. Illnait,et al.  A Long-Term Study of Policosanol in the Treatment of Intermittent Claudication , 2001, Angiology.

[26]  Tyson Vc.  Treatment of intermittent claudication. , 1979 .

[27]  M. Ramirez-Tortosa,et al.  Sunflower oil does not protect against LDL oxidation as virgin olive oil does in patients with peripheral vascular disease. , 2004, Clinical nutrition.

[28]  R. Collins,et al.  Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. , 1997, European heart journal.

[29]  G. Leng,et al.  Lipid-lowering for lower limb atherosclerosis. , 1998, The Cochrane database of systematic reviews.

[30]  B. Lewis,et al.  TREATMENT OF HYPERLIPIDAEMIA RETARDS PROGRESSION OF SYMPTOMATIC FEMORAL ATHEROSCLEROSIS A Randomised Controlled Trial , 1983, The Lancet.

[31]  G. Lowe,et al.  Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. , 1998, Clinical nutrition.

[32]  D. Betteridge.  INTERNATIONAL MULTICENTRE COMPARISON OF CERIVASTATIN WITH PLACEBO AND SIMVASTATIN FOR THE TREATMENT OF PATIENTS WITH PRIMARY HYPERCHOLESTEROLAEMIA , 1999, International journal of clinical practice.

[33]  K. Ferdinand,et al.  Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia. , 2000, Journal of the National Medical Association.

[34]  J. O'Hara,et al.  The therapeutic efficacy of inositol nicotinate (Hexopal ® ) in intermittent claudication: a controlled trial , 1988, The British journal of clinical practice.

[35]  G. Agnelli,et al.  Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. , 2002, European heart journal.

[36]  E. Marrapodi,et al.  The Effectiveness of Glycosaminoglycans in Peripheral Vascular Disease Therapy: A Clinical and Experimental Trial , 1985, The Journal of international medical research.

[37]  J. O'Hara.  A double-blind placebo-controlled study of Hexopal in the treatment of intermittent claudication. , 1985, The Journal of international medical research.

[38]  R H Selzer,et al.  Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[39]  B. Griffin,et al.  Compliance to multiple interventions in a high risk population. , 1999, Annals of epidemiology.

[40]  Andrew Briggs,et al.  Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals , 2005, The Lancet.

[41]  M. Mercuri,et al.  Effects of 3-Glucosaminoglycan Sulfate on Hemorheologic Parameters in Hyperlipidemic Peripheral Vascular Disease (PVD) Patients , 1989, Angiology.

[42]  G. Davı̀,et al.  Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use. , 1990, Atherosclerosis.

[43]  S. Nilsson,et al.  The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). , 1994, The American journal of cardiology.

[44]  Mark A. Creager,et al.  Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease , 2003, Circulation.

[45]  S. Humphries,et al.  Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. , 2002, Atherosclerosis.

[46]  A. Jacob,et al.  Effects of Probucol versus Aspirin and versus Brachytherapy on Restenosis after Femoropopliteal Angioplasty: The PAB Randomized Multicenter Trial , 2004, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[47]  M. Kissin,et al.  The Effect of Drugs Used in the Treatment of Inter Mittent Claudication On the Exercise Tolerance of Individuals With Obliterating Arteriosclerosis , 1951, Angiology.

[48]  R. Gans,et al.  Fish oil supplementation in patients with stable claudication. , 1990, American journal of surgery.

[49]  P. Antignani,et al.  Experiences with sulodexide in the arterial peripheral diseases , 1984 .

[50]  P. Russo,et al.  Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease. , 2001, Clinical therapeutics.

[51]  R. Prescott,et al.  Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. , 1991, International journal of epidemiology.

[52]  S. Sb.  Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease , 1997 .

[53]  A. Coats.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[54]  E. Stipa,et al.  The use of sulodexide in the treatment of peripheral vasculopathy accompanying metabolic diseases. Controlled study in hyperlipidemic and diabetic subjects. , 1986, Thrombosis research.

[55]  E. Palazzini,et al.  Clinical evaluation of a native low molecular weight heparin in the management of symptomatic peripheral vasculopathy in the elderly , 1987 .

[56]  W. Applegate,et al.  Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. , 2000, American heart journal.

[57]  J. Price,et al.  Risk of mortality and cardiovascular disease associated with the ankle-brachial index: Systematic review. , 2006, Atherosclerosis.

[58]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[59]  Kiff Rs,et al.  Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial. , 1988 .

[60]  Alan S. Brown,et al.  Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. , 1998, Journal of the American College of Cardiology.

[61]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[62]  J. Mataix,et al.  Effect of extra-virgin olive oil and fish-oil supplementation on plasma lipids and susceptibility of low-density lipoprotein to oxidative alteration in free-living spanish male patients with peripheral vascular disease. , 1999, Clinical nutrition.

[63]  S. Azen,et al.  Effects of colestipol-niacin therapy on human femoral atherosclerosis. , 1991, Circulation.

[64]  J. Illnait,et al.  Effects of Policosanol and Ticlopidine in Patients with Intermittent Claudication: A Double-Blinded Pilot Comparative Study , 2004, Angiology.

[65]  A. Iorio,et al.  Increased Plasma Levels of Tissue Factor Pathway Inhibitor (TFPI) after n-3 Polyunsaturated Fatty Acids Supplementation in Patients with Chronic Atherosclerotic Disease , 1996, Thrombosis and Haemostasis.

[66]  J. Dumville,et al.  The health-related quality of life of people with peripheral arterial disease in the community: the Edinburgh Artery Study. , 2004, The British journal of general practice : the journal of the Royal College of General Practitioners.

[67]  R. Collins,et al.  MRC BHFHeart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience , 1999 .

[68]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[69]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[70]  Y. Ouchi,et al.  A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE). , 2001, Journal of atherosclerosis and thrombosis.

[71]  T. Meade.  Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621] , 2001, Current controlled trials in cardiovascular medicine.

[72]  N. Fiotti,et al.  Treatment of Intermittent Claudication with Antiplatelet Agents , 1990, The Journal of international medical research.

[73]  S. Mondillo,et al.  Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. , 2003, The American journal of medicine.

[74]  G. Bonanno,et al.  Sulodexide in the treatment of atherosclerosis: a controlled clinical trial , 1985 .

[75]  G. Crepaldi,et al.  Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial. , 1986, Monographs on atherosclerosis.

[76]  G. Walldius,et al.  The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). , 1993, The American journal of cardiology.

[77]  J. Cooke,et al.  Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar® , 2000 .

[78]  T. Meade,et al.  Bezafibrate in men with lower extremity arterial disease: randomised controlled trial , 2002, BMJ : British Medical Journal.

[79]  D. Hunninghake,et al.  Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. , 2000, JAMA.

[80]  K. Hutchison,et al.  Effects of dietary manipulation on vascular status of patients with peripheral vascular disease. , 1983, JAMA.

[81]  A. Head.  Treatment of intermittent claudication with inositol nicotinate. , 1986, The Practitioner.

[82]  R. Collins,et al.  Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. , 1994, European heart journal.

[83]  J. Kostis,et al.  Effect of niacin supplementation on fibrinogen levels in patients with peripheral vascular disease. , 1998, The American journal of cardiology.

[84]  E. Davis,et al.  Xanthinol nicotinate in peripheral vascular disease. , 1975, The Practitioner.

[85]  F. Fowkes,et al.  Epidemiology of atherosclerotic arterial disease in the lower limbs. , 1988, European journal of vascular surgery.

[86]  T. Mori,et al.  Plasma lipid levels and platelet and neutrophil function in patients with vascular disease following fish oil and olive oil supplementation. , 1992, Metabolism: clinical and experimental.

[87]  Smith Rs,et al.  Effect of nicotinic acid and dipyridamole on tissue blood flow in peripheral vascular disease. , 1981 .

[88]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[89]  Peters Ll.  DRUG TREATMENT IN PSYCHIATRY. , 1964 .

[90]  R. Collins,et al.  The MRC/BHF Heart Protection Study: preliminary results. , 2002, International journal of clinical practice.

[91]  J. Illnait,et al.  A Double-Blind, Placebo-Controlled Study of the Effects of Policosanol in Patients with Intermittent Claudication , 1999, Angiology.

[92]  J. Mataix,et al.  Olive oil- and fish oil-enriched diets modify plasma lipids and susceptibility of LDL to oxidative modification in free-living male patients with peripheral vascular disease: the Spanish Nutrition Study , 1999, British Journal of Nutrition.

[93]  M. Lunetta,et al.  Lowering of Plasma Viscosity by the Oral Administration of the Glycosaminoglycan Sulodexide in Patients with Peripheral Vascular Disease , 1992, The Journal of international medical research.

[94]  Roberto G. Carbone,et al.  Octreoscan perspectives in sarcoidosis and idiopathic interstitial pneumonia. , 2003, European review for medical and pharmacological sciences.

[95]  T. Szucs,et al.  Cost of Treating to a Modified European Atherosclerosis Society LDL-C Target , 1999 .

[96]  H. Rasmussen,et al.  The peripheral circulation and treatment of hyperlipoproteinemias. , 1983, Atherosclerosis.

[97]  T. Wilt,et al.  Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. , 1999, The American journal of cardiology.